high protein foods for glp 1 diet The GLP-1 effect: Reformulating high-protein, nutrient-packed demand 2025 Expert Guide: Best Protein

Stossi, F., Madak-Erdogan, Z

It's that easy

placebo INDIANAPOLIS, May 21, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, in adults with obesity or overweight and at least one weight-related comorbidity and without diabetes

To find out if your Aetna plan covers Zepbound, contact Aetna using the phone number on your insurance card or logging into your member website

higher values seen with off-label use at maximum doses